Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon7.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ITCH, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ITCH also known as AIP4 is an E3 ubiquitin ligase with a molecular mass of approximately 108 kDa. The protein primarily functions in the ubiquitination process which regulates protein degradation via the proteasome. ITCH is known for its role in the post-translational modification of proteins through ubiquitin tagging facilitating the promotion or suppression of signal transduction pathways. Expression of ITCH occurs in various tissues including lymphocytes and epithelial cells indicating its diverse functional roles in different physiological contexts.
Biological function summary
ITCH/AIP4 is integral in cellular regulatory mechanisms. It forms part of a sophisticated complex involved in immune response modulation cell cycle regulation and apoptosis. ITCH influences T-cell receptor signaling by controlling the degradation of proteins involved in these critical pathways. Through the ubiquitination cascade ITCH maintains cellular homeostasis participating in the intricate balance of protein synthesis and degradation necessary for normal cellular function.
Pathways
ITCH/AIP4 plays essential roles in the T-cell receptor and Wnt signaling pathways. It interacts with other proteins such as NEDD4 and CBL which are also E3 ubiquitin ligases to modulate signaling cascades involved in immune responses and cellular growth. In the Wnt pathway ITCH regulates the stability of Dishevelled proteins thereby affecting cellular proliferation and differentiation processes. This involvement in multiple pathways highlights its regulatory versatility and importance in maintaining cellular balance.
ITCH/AIP4 is associated with autoimmune diseases and cancer. Its dysfunction can lead to abnormal immune responses contributing to conditions such as systemic lupus erythematosus. Moreover the protein's role in oncogenesis is linked to its ability to modify tumor suppressor and oncoprotein levels including p53 and c-Jun. Disruption in ITCH's function can result in unchecked cell growth and survival emphasizing its potential as a therapeutic target in cancer treatment.
